25th week of 2010 patent applcation highlights part 48 |
Patent application number | Title | Published |
20100158794 | HEAT PIPE, HEAT PIPE REFORMER COMPRISING SUCH A HEAT PIPE, AND METHOD FOR THE OPERATION OF SUCH A HEAT PIPE REFORMER - A heat pipe and a method for operating a heat pipe of said type are provided, which heat pipe remains active over a relatively long period of time in particular when used in pressurized gasification atmosphere, that is to say in a hydrogen-rich environment. Also specified is a heat pipe reformer having a heat pipe of said type. By providing a hydrogen extractor in the region of the heat-dissipating end of the heat pipe, the hydrogen which has penetrated into the heat pipe and accumulated there is conducted out of the heat pipe again, such that the heat-exchanging capacity of the heat pipe is maintained. The hydrogen extractor generates a hydrogen concentration gradient or a hydrogen partial pressure gradient between the interior and the exterior of the pipe casing, such that hydrogen which has penetrated into the interior of the heat pipe is diffused into the hydrogen extractor and can be extracted from there. A hydrogen concentration gradient or hydrogen partial pressure gradient is also formed between the atmosphere surrounding the heat pipe, for example the atmosphere in a reforming fluidized-bed gasification chamber, and the hydrogen extractor, such that hydrogen from the surrounding atmosphere is also diffused into the hydrogen extractor and extracted from there. | 2010-06-24 |
20100158795 | METHODS AND SYSTEMS FOR ASSESSING LUNG FUNCTION AND DELIVERING THERAPEUTIC AGENTS - Methods and systems for isolating, assessing and treating lung compartments are disclosed. One or more lung compartments are accessed through an isolation catheter, oxygen rich gas is delivered to the compartments, and blood oxygen or exhaled carbon dioxide are monitored to assess lung compartment function. Diseased lung compartments may be treated using therapeutic agents delivered to the diseased compartments through the isolation catheter. Therapeutic agents include carbon monoxide, radioactive agents, chemotherapeutic agents or angiogenesis inhibitors and angiocidal agents. | 2010-06-24 |
20100158796 | AMIDES OF HYALURONIC ACID AND THE DERIVATIVES THEREOF AND A PROCESS FOR THEIR PREPARATION - An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (1).: wherein R═NR | 2010-06-24 |
20100158797 | USE OF A2A ADENOSINE RECEPTOR AGONISTS - Myocardial imaging methods that are accomplished by administering doses of a pharmaceutical composition including regadenoson—an adenosine A | 2010-06-24 |
20100158798 | FP-Pocket-Binding Effectors and Methods for Using the Same to Modulate Telomerase Activity - The present invention embraces compounds selected for interacting with the Fingers-Palm pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase. | 2010-06-24 |
20100158799 | METHOD AND COMPOSITION FOR BIOACTIVE AGENT RELEASE IN VIVO - A composition for bioactive agent release in vivo. The composition includes the bioactive agent in combination with a mixture of a first polymer component such as poly(butyl methacrylate) and a second polymer component such as poly(ethylene-co-vinyl acetate). | 2010-06-24 |
20100158800 | DRUG DEPOT IMPLANT DESIGNS AND METHODS OF IMPLANTATION - The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement. | 2010-06-24 |
20100158801 | METHODS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA - This invention relates to the staging, diagnosis and treatment of cancerous diseases (both primary tumors and tumor metastases), particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of isolated monoclonal antibodies, antigen binding fragments thereof, and/or cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more CDMAB, chemotherapeutic agents, and conjugates thereof, as a means for initiating a cytotoxic response to human hematologic malignancies. The invention further relates to binding assays, which utilize the isolated monoclonal antibodies, antigen binding fragments thereof, and/or CDMAB of the instant invention. The cancerous disease modifying antibodies antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells. | 2010-06-24 |
20100158802 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies - The present invention provides humanized, chimeric and human anti-CSAp antibodies and anti-CSAp antibody fusion proteins that are useful for the treatment and diagnosis of various cancers, including colon cancer. | 2010-06-24 |
20100158803 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies - The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them. | 2010-06-24 |
20100158804 | METHOD FOR THE USE OF [11C] CARBON MONOXIDE IN LABELING SYNTHESIS OF 11C-LABELLED ESTERS AND ACIDS BY SENSITIZED PHOTO-INDUCED FREE RADICAL CARBONYLATION - Methods and reagents for photo-initiated carbonylation with carbon-isotope labeled carbon monoxide using alkyl/aryl iodides with alcohols or water treated by photosensitizers are provided. The resultant carbon-isotope labeled esters and acids, and pharmaceutical acceptable salts and solvates are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). Associated kits and method for PET studies are also provided. | 2010-06-24 |
20100158805 | QUANTUM DOT LABELED STEM CELLS FOR USE IN CARDIAC REPAIR - The present invention provides methods and compositions relating to the labeling of target cells with quantum dots (QDs). Specifically, a delivery system is disclosed based on the use of negatively charged QDs for delivery of a tracking fluorescent signal into the cytosol of target cells via a passive endocytosis-mediated delivery process. In a specific embodiment of the invention the target cell is a stem cell, preferably a mesenchymal stem cell (MSC). Such labeled MSCs provide a means for tracking the distribution and fate of MSCs that have been administered to a subject to promote cardiac repair. The invention is based on the discovery that MSCs can be tracked in vitro for up to at least 6 weeks. Additionally, QDs delivered in vivo can be tracked for up to at least 8 weeks, thereby permitting for the first time, the complete 3-D reconstruction of the locations of all MSCs following administration into a host. | 2010-06-24 |
20100158806 | Compositions for Delivery of Therapeutics and Other Materials - This disclosure relates to compositions for delivering agents to a subject, and in particular, to compositions for delivery of therapeutic agents or diagnostic agents in the presence or absence of targeting moieties. In part, this disclosure relates to compositions comprising a hydrophobic group with a first end and a second end, a first metal binding domain linked to the hydrophobic group, a metal ion capable of being chelated to the first metal binding domain, and an agent linked to a second metal binding domain capable of chelating to the metal ion. | 2010-06-24 |
20100158807 | RECEPTOR - We disclose a method of treating or preventing a disease selected from the group consisting of: a bladder disease, a bladder disorder, benign prostatic hyperplasia, bladder outlet obstruction, incontinence, including overflow and urge incontinence, urinary urge, cystitis, including interstitial cystitis and overactive bladder. | 2010-06-24 |
20100158808 | Altered Activity of Toll-Like Receptors - Materials and Methods for modulating TLR activity are described, as well as methods for reducing body fat and increasing bone density. | 2010-06-24 |
20100158809 | TRUNCATED PAP2 AND METHODS OF MAKING AND USING SAME - A method of treating pancreatitis is provided, including the steps of: providing a mammal having pancreatitis; and administering a therapeutically effective amount of a truncated N-terminal PAP2; and making of an antibody specifically directed to detect PAP2. | 2010-06-24 |
20100158810 | Enhanced 13C NMR By Thermal Mixing With Hyperpolarized 129XE - A method of preparing a hydrogen-containing | 2010-06-24 |
20100158811 | ASSESSING BRAIN ANEURYSMS - This document provides methods and materials related to assessing brain conditions within mammals. For example, methods and materials that can be used to determine whether or not a mammal (e.g., a human) with a brain aneurysm is likely to experience brain aneurysm rupture are provided. | 2010-06-24 |
20100158812 | Anti-Cancer Medicine Both for Diagnosing and Treating Cancer - Disclosed is an anti-cancer medicine comprising a chain end functionalized polymer, a contrast material such as iron oxide and a chemotherapeutic agent such as doxorubicin or pharmaceutically acceptable salts thereof. The anti-cancer medicine performs diagnosis and treatment of cancer at the same time, remarkably reduces a cardiotoxic side effect of the doxorubicin and has an excellent targeting function to the cancer part to considerably increase the anti-cancer effect. At the same time, the anti-cancer medicine is provided as MRI contrast medium which can diagnose the cancer and monitor a progress of the disease. In particular, the anti-cancer medicine is disclosed which is superior to the diagnosis and treatment of the solid cancer and can effectively perform the diagnosis and treatment of the metastatic cancer as well as the primary cancer at the same time. | 2010-06-24 |
20100158813 | MICROBUBBLES AS DRUG DELIVERY DEVICE - A method of making PVA microbubbles including a functionalisation step in which PVA polymeric chains are functionalised at their ends with aldehyde groups, and a subsequent cross-linking step, in which in an air-aqueous solution emulsion with a pH between 4.5 and 5.5 the previously functionalised PVA polymeric chains cross-link by means of an acetalisation reaction, thereby forming the microbubbles. The microbubbles produced are subsequently subjected to a lyophilising step, a filling step in which medicinal gas is introduced and a restoration step of the microbubbles by adding an aqueous solution. | 2010-06-24 |
20100158814 | Fibrin-Binding Peptides and Conjugates Thereof - Fibrin-binding peptides having high binding affinity and excellent physical characteristics compared to previously known fibrin-binding peptides are provided. These fibrin-binding peptides may be conjugated to a detectable label or a therapeutic agent and used to detect and facilitate treatment of pathological conditions associated with the presence of fibrin such as thrombic, angiogenic and neoplastic conditions. These peptides may be used in imaging processes such as MRI, ultrasound and nuclear medicine imaging (e.g. PET, scintigraphic imaging., etc.). The peptides may also be used therapeutically. The present invention also provides processes and methods for making and using such peptides and conjugates thereof. | 2010-06-24 |
20100158815 | Biological Cell Tracking With Ultrasound - This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure. | 2010-06-24 |
20100158816 | GAS BUBBLE-GENERATING AGENT - This invention provides a gas bubble-generating agent that can be used as a contrast medium or a blocking agent in vivo. Such gas bubble-generating agent is produced by a method for producing a gas bubble-generating agent comprising the following steps of: (a) preparing a mixed solution of an amphiphilic substance, an amphiphilic substance comprising a water-soluble polymer chemically bound thereto, a hardly water-soluble substance having a boiling point of lower than 60° C. at atmospheric pressure, and a physiologically acceptable isotonic solution; (b) pressurizing the mixed solution; and (c) centrifuging the mixed solution after the step of pressurization, wherein a molar concentration of the amphiphilic substance in the mixed solution prepared in step (a) is 10 times or more higher than that of the amphiphilic substance comprising a water-soluble polymer chemically bound thereto. | 2010-06-24 |
20100158817 | T1 MRI TRACKABLE DRUG DELIVERY PARTICLES, USES AND METHODS THEREOF - The current invention discloses a drug delivery system allowing monitoring of spatial position and drug release, as well as methods and uses thereof. More particularly, the drug delivery system comprises drug carrying particles comprising an internal and external distribution of magnetic resonance imaging contrast agents. | 2010-06-24 |
20100158818 | ANTIMICROBIAL N-CHLORINATED COMPOSITIONS - The present application relates to N-chlorinated cationic compounds of Formula I | 2010-06-24 |
20100158819 | Calcium Glycerophosphate for Treating and Preventing Respiratory Diseases or Conditions - Calcium glycerophosphate is found to be effective in treating and preventing a disease, disorder and/or condition of the respiratory system. The disease, disorder and/or condition is related to an obstructive or a restrictive condition of the respiratory airway. The disease, disorder and/or condition can be a respiratory airway inflammatory disease, a respiratory airway stenosis or a nasal cavity inflammatory disease, such as an asthma, a chronic obstructive pulmonary disease (COPD), an emphysema, a reactive airway disease (RADS), rhinitis, bronchitis, bronchiolitis, congestion, sinusitis, tonsillitis, or laryngitis, post-nasal drip (PND) and a related complication thereof, inflamed degranulating and non-degranulating mast cell activity, any irritation occasioning mucus secretion from goblet cells breathing difficulty, restriction, obstruction; airways constriction or closure or mucus interference with air passage; sleep apnea, snoring, inflammatory or non-inflammatory responses to an airborne or non-airborne allergen or irritant; nasal or non-nasal airway inflammation or irritation caused by a problem in any area of the body; and a physical damage to the respiratory system. Methods, compositions and devices are described for using calcium glycerophosphate to treat and prevent the disease, disorder and/or condition of the respiratory system. | 2010-06-24 |
20100158820 | XYLITOL DENTAL MAINTENANCE SYSTEM - A system, kit and method for promoting oral hygiene are disclosed. The kit may comprise several compositions or a single composition, each of which comprises an effective amount of xylitol. For example, the system and kit may comprise a chewing gum composition, a morsel composition, a paste-like composition, and an oral rinse composition; or any one of the above compositions; or any combination of the above compositions. It will be appreciated that a novel method for using such a system and kit for promoting oral hygiene may include: administering about 0.5 grams to about 2.0 grams of xylitol through the paste-like composition in the morning and in the evening, administering about 0.5 grams to about 2.0 grams of xylitol after consumption of nutrition through chewing the gum composition or through the morsel composition, and administering about 0.5 grams to about 1.5 grams of xylitol per application through the oral rinse composition. | 2010-06-24 |
20100158821 | ANTIMICROBIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING THE SAME, AND METHODS OF USING THE COMPOSITIONS AND PRODUCTS - Antimicrobial agents, products and compositions incorporating the agents, and methods of using the compositions and products are provided. The antimicrobial agents comprise 1,2-cyclohexanedimethanol, 1,4-cyclohexanedimethanol, 2,2,4,4-tetramethyl-1,3-cyclobutanediol, or mixtures thereof. These agents have surprisingly been found to inhibit microbial growth at a much lower concentration than other glycols with known antimicrobial activity. | 2010-06-24 |
20100158822 | PEPTIDES THAT BIND TO SILICA-COATED PARTICLES - Peptides having strong affinity for silica as well as surfaces comprising silica are described. The silica-binding peptides may be used to construct peptide based-reagents suitable for delivery of a silica-coated particulate benefit agent to a surface, such as body surface, for personal care and cosmetic applications. Peptide-based reagents formed by coupling at least one of the silica-binding peptides to at least one body surface-binding peptide, either directly or through a spacer, are described. The peptide-based reagents may be used in conjunction with at least one silica-coated colorant to color body surfaces. | 2010-06-24 |
20100158823 | PEPTIDE LINKERS FOR EFFECTIVE MULTIVALENT PEPTIDE BINDING - Short single chain peptides having affinity for a target surface often lack the binding durability required for certain commercial applications. One way to improve durability is to promote multivalent binding by linking together binding sequences using peptide linkers. However, the resulting single chain binding peptides often suffer from linker entropy. It has been discovered that the use of rigid peptide linkers when linking together multiple binding sequences enhances the binding affinity of the resulting single chain peptide. | 2010-06-24 |
20100158824 | SILICONE POLYETHER ELASTOMER GELS - Gel compositions are disclosed containing a silicone polyether elastomer from the reaction of an organohydrogensiloxane having at least two SiH containing cyclosiloxane rings in its molecule, a compound or mixture of compounds having at least two aliphatic unsaturated groups in its molecule, and a hydrosilylation catalyst. The silicone polyether elastomer reaction product may itself be a gelled composition, or optionally may be contained in a carrier fluid to form a gel. The gel compositions may further contain a personal or healthcare active. | 2010-06-24 |
20100158825 | COSMETIC AND PERSONAL CARE PRODUCTS CONTAINING SYNTHETIC MAGNESIUM ALUMINO-SILICATE CLAYS - The invention provides for cosmetic and personal care compositions comprising a synthetic magnesium aluminosilicate clay. The synthetic magnesium aluminosilicate clay is formed at ambient pressure by a series of reaction steps and a pH change from acidic pH to basic pH. The characteristics of the magnesium aluminosilicate clay, including platelet size, degree of stacking, and porosity can be tuned depending on the cosmetic or personal care product desired. In addition, these cosmetic and personal care compositions optionally include one or more of the following components: odor controlling agents, skin protectants, diluents, lipophilic skin health benefit agents, sunscreens, humectants, emollients, slip compounds, and moisturizers. | 2010-06-24 |
20100158826 | COMPOSITIONS COMPRISING SELF-TANNING AGENTS AND SUGAR AMINES - The present invention relates to a composition for darkening the skin. The composition includes a self-tanning agent and a sugar amine. In another aspect, a method of darkening the skin includes topically applying the above composition to the skin. | 2010-06-24 |
20100158827 | COMPOSITIONS COMPRISING SELF-TANNING AGENTS AND PLANT EXTRACTS - The present invention relates to a composition for darkening the skin. The composition includes a self-tanning agent, and a plant extract selected from the group consisting of extract of pre-germinated soy seeds, walnut seed extract, mugwort extract, and combinations thereof. In another aspect, a method of darkening the skin includes topically applying the above composition to the skin. | 2010-06-24 |
20100158828 | Topical Compositions Containing CIS-6-Nonenol and its Derivatives and Methods for Treating Skin - Cosmetic compositions comprising cis-6-nonenol and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. Cis-6-nonenol is believed to have modulatory activity against at least one biochemical pathway implicated in skin aging. | 2010-06-24 |
20100158829 | Method and Composition for Color Modulation - The invention is directed to a method and composition suitable for skin color modulation. Particularly, the action of D-dopachrome tautomerase on melanogenesis and/or the transfer of melanin from melanosomes in keratinocytes is reduced, thereby resulting in a change in skin color. | 2010-06-24 |
20100158830 | Multiphase Personal Care Composition With Enhanced Deposition - A multiphase personal care composition that comprises a structured surfactant phase and an oil continuous benefit phase. The structured surfactant phase comprises from about 5% to about 30% of a mixture of lathering surfactants, a lamellar inducing agent and a cationic polymer. The oil continuous benefit phase comprises a hydrocarbon based benefit material and a low HLB emulsifier. The low HLB emulsifier comprises an unsaturated monoglyceryl ester having from about 14 to about 30 carbon atoms. The oil continuous benefit phase comprises a ratio of said hydrocarbon based benefit materials to said low HLB emulsifier comprising from about 30:1 to about 200:1. | 2010-06-24 |
20100158831 | Viscosity Regulator, Method For The Production Thereof, And Use Thereof - The present invention relates to a method for the production of a viscosity regulator by introducing hydrophobic and hydrophilic groups into a starch molecule. The invention also relates to viscosity regulators produced in this manner and the use thereof. The viscosity regulators according to the invention can be used as emulsifiers or as thickening agents of surfactant-containing systems, e.g. in cosmetic or pharmaceutical preparations. | 2010-06-24 |
20100158832 | COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR POLYMER AND METHOD FOR MAKING UP THE SKIN AND/OR LIPS EMPLOYING A COMPOSITION COMPRISNG A SUPRAMOLECULAR POLYMER - The present disclosure relates to a method for making up the skin and/or lips, wherein a cosmetic makeup composition comprising, in a cosmetically acceptable medium, at least one polyalkene-based supramolecular polymer is applied. The disclosure also relates to a cosmetic composition for making up the skin and/or lips, comprising, in a cosmetically acceptable medium, at least one polyalkene-based supramolecular polymer and at least one coloring material. | 2010-06-24 |
20100158833 | COMPOSITIONS COMPRISING SELF-TANNING AGENTS AND PLANT EXTRACTS - The present invention relates to a composition for darkening the skin. The composition includes a self-tanning agent, and a plant extract selected from the group consisting of extract of pre-germinated soy seeds, walnut seed extract, mugwort extract, and combinations thereof. In another aspect, a method of darkening the skin includes topically applying the above composition to the skin. | 2010-06-24 |
20100158834 | COMPOSITION COMPRISING AT LEAST TWO DIFFERENT CYCLOALKYLMETHICONES AND USE THEREOF - A cosmetic composition includes comprising a blend of cycloalkylmethicones comprising at least two different cycloalkylmethicones having general formula I: | 2010-06-24 |
20100158835 | PLASTICIZER OF NATURAL ORIGIN FOR NAIL POLISH - The use of at least one carbonate of natural origin as a plasticizer in a film-forming cosmetic composition comprising, in a physiologically acceptable medium, a film-forming polymer and a solvent medium. | 2010-06-24 |
20100158836 | Method of Coloring Nails and a Nail Polish Formulation - Various embodiments of this invention discloses a translucent and colored nail polish glaze, a nail polish base, and a method for combining nail polish base colors with translucent and colored nail polish glazes to create a multiple of different colors and color shades from a minimal number of nail polish base and glaze colors. | 2010-06-24 |
20100158837 | IRON OXIDE-BINDING PEPTIDES - Peptides having strong affinity for iron oxide pigment particles have been identified. Peptide-based reagents comprising at least one of the present iron oxide-based pigment-binding peptides and at least one body surface-binding peptide are described. The peptide-based reagents may be used in conjunction with at least one iron oxide-based pigment to color body surfaces. | 2010-06-24 |
20100158838 | NAIL VARNISH COMPRISING A SICCATIVE OIL AND A METAL SALT - The present invention relates to a nail varnish, characterized in that it comprises at least one siccative oil and at least one metal salt, and in that it comprises less than 5% by weight of volatile organic solvent(s) relative to the total weight of the nail varnish. | 2010-06-24 |
20100158839 | OXIDIZING COMPOSITION FOR THE TREATMENT OF KERATIN FIBERS COMPRISING AT LEAST ONE CATIONIC POLYMER, AT LEAST ONE FATTY AMIDE AND AT LEAST ONE ANTI-OXYGEN AGENT - Provided is a composition for the treatment of keratin fibers, for example human keratin fibers such as the hair, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition ranges from 1.5 to 4.5. Also provided is a composition for the treatment of keratin fibers, comprising, in a cosmetically acceptable medium, at least one cationic polymer; at least one fatty amide; at least one anti-oxygen agent; and at least one oxidizing agent; wherein the pH of the composition is alkaline. Also provided is a method for treating keratin fibers, comprising applying, to the keratin fibers, at least one oxidizing composition described herein. | 2010-06-24 |
20100158840 | DEODORANT COMPOSITION - The present invention relates to a deodorant composition containing (a) a polyphenol compound or a plant extract containing a polyphenol compound, (b) a basic substance, and (c) a metal salt. The deodorant composition of the present invention is capable of providing a deodorizing effect in a short period of time when it is applied to a malodor source, is capable of providing an excellent deodorizing activity and is also excellent in the store stability. | 2010-06-24 |
20100158841 | DEODORANT COMPOSITIONS - A gelled composition is provided which comprises:
| 2010-06-24 |
20100158842 | NATURAL SKIN WHITENER: 4-HYDROXY-OXINDOLE-3-ACETIC ACID - A cosmetic and dermatological composition comprises 2, 3-dihydro-4-hydroxy-2-oxo-1-H-indole-3-acetic acid (4-hydroxy-1-oxindole-3-acetic acid) as an active ingredient for use as a melanin inhibitor and as an anti-tyrosinase enzyme inhibitor. This composition is excellent as a skin whitening agent. Since it also has potent antioxidant and anti-irritant activities it is useful in a cosmetic composition for improving hyperpigmentation disorders of the skin. | 2010-06-24 |
20100158843 | NOVEL 3-PHENYLPROPANOIC COMPOUND ACTIVATORS OF RECEPTORS OF PPAR TYPE AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF - Novel 3-phenylpropanoic acid compounds have the general formula (I) below: | 2010-06-24 |
20100158844 | OXIDIZING COMPOSITION FOR THE TREATMENT OF KERATIN FIBERS COMPRISING AT LEAST ONE OIL, ATLEAST ONE FATTY ALCOHOL AND AT LEAST ONE OXYALKYLENATED FATTY ALCOHOL - Provided herein is a composition for the treatment of keratin fibers comprising, a cosmetically acceptable medium; at least one fatty alcohol; at least one oxyalkylenated fatty alcohol; at least one oxidizing agent; and at least one oil other than a fatty alcohol present in an amount greater than or equal to 10% by weight relative to the total weight of the composition, wherein the weight ratio of the at least one fatty alcohol to the at least one oxyalkylenated fatty alcohol has a value less than or equal to 5; and further wherein the pH of the composition ranges from 1.5 to 4.5. Also provided herein is a composition for the treatment of keratin fibers comprising, a cosmetically acceptable medium; at least one fatty alcohol present in an amount ranging from 3 to 25% by weight relative to the total weight of the composition; at least one oxyalkylenated fatty alcohol; at least one oxidizing agent; and at least one oil other than a fatty alcohol present in an amount greater than or equal to 10% by weight relative to the total weight of the composition, wherein the weight ratio of the at least one fatty alcohol to the at least one oxyalkylenated fatty alcohol has a value less than or equal to 5; and further wherein the pH of the composition is alkaline. Also provided herein is a method for treating keratin fibers, comprising applying to the keratin fibers at least one oxidizing composition described herein. | 2010-06-24 |
20100158845 | COMPOSITION AND PROCESS FOR RELAXING OR STRAIGHTENING HAIR - The present invention is directed to composition for straightening or relaxing hair containing: (a) at least one hydroxide-containing active ingredient; (b) at least one polyhydric alcohol having 4 or more carbon atoms and two hydroxyl groups; (c) optionally, at least one nonionic surfactant having an HLB of from about 8 to about 20; (d) optionally, at least one amphoteric and/or zwitterionic surfactant; and (e) remainder, to 100%, of a cosmetically suitable medium. | 2010-06-24 |
20100158846 | HAIR-BINDING PEPTIDES - Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided. | 2010-06-24 |
20100158847 | HAIR-BINDING PEPTIDES - Hair-binding peptides were isolated for their use in a variety of personal care formulations and applications. The isolation of hair-binding peptides was accomplished by enrichment using mRNA-display selection technology. Hair care compositions comprising peptide-based reagents prepared comprising the hair-binding peptides are also provided. | 2010-06-24 |
20100158848 | COSMETIC COMPOSITION COMPRISING A BRANCHED SULPHONIC POLYESTER AND A SURFACTANT AND USES IN HAIR STYLING - The present application relates to a cosmetic composition comprising, in a cosmetically acceptable medium: at least one branched sulphonic polyester, and at least one non-ionic oxyalkylenated or glycerolated surfactant. The present application also relates to the uses of this composition, for example for the styling and the shaping of the hair. | 2010-06-24 |
20100158849 | ISOCYANATE TERMINATED MACROMER AND FORMULATION THEREOF FOR USE AS AN INTERNAL ADHESIVE OR SEALANT - A novel macromer or mixture thereof is described herein, comprising isocyanatophenyl ether terminal moieties and at least two residues of a water-soluble polymer having a molecular weight ranging from 80 to 10,000 adjacent to the ether group of the isocyanatophenyl ether terminal isocyanate moieties, thereby forming at least two ether linkages in the macromer or mixture thereof. A method for making a polyisocyanate macromer is also described herein. | 2010-06-24 |
20100158850 | DENDRIMER BASED MODULAR PLATFORMS - The present invention relates to novel therapeutic and diagnostic dendrimer based modular platforms (e.g., drug delivery platforms). In particular, the dendrimer based modular platforms are configured such that two or more dendrimers (e.g., PAMAM dendrimers) are coupled together (e.g., via a cycloaddition reaction) wherein each of the coupled dendrimers is functionalized (e.g., functionalized for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy). In some embodiments, the present invention provides dendrimer based modular platforms having coupled dendrimers (e.g., two or more coupled dendrimers) wherein each dendrimer is conjugated to one or more functional groups (e.g., therapeutic agent, imaging agent, targeting agent, triggering agent) (e.g., for specific targeting and/or therapeutic use of the dendrimer based modular platform). In some embodiments, the functional groups are conjugated to the dendrimers via a linker and/or a triggering agent. In addition, the present invention is directed to methods of synthesizing dendrimer based modular platforms, compositions comprising the dendrimer based modular platforms, as well as systems and methods utilizing the dendrimer based modular platforms (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, etc.)). | 2010-06-24 |
20100158851 | MATERIAL FOR FORMING A MULTI-LEVEL ANTIMICROBIAL SURFACE COATING AND ITS PREPARATION - The present invention provides a material for forming an antimicrobial surface coating with multi-level antimicrobial properties, which comprises one or more volatile or gaseous biocides, one or more nonvolatile biocides, and one or more polymers, wherein the volatile or gaseous biocides are encapsulated in the polymers to provide a sustained release of the volatile or gaseous biocides. The present invention further provides a method for preparing the material. | 2010-06-24 |
20100158852 | METHOD FOR REDUCTION OF MICROBES ON SURFACES - A method has been found for the removal of microbial biofilm on surfaces in contact with systems, including but not limited to aqueous systems, which comprises adding to the aqueous system an effective amount of a polyalkyleneoxide polysiloxane surfactant to substantially remove microbial biofilm, from surfaces in aquatic systems, while presenting minimal danger to non-target aquatic organisms at discharge due to their very low discharge concentrations. | 2010-06-24 |
20100158853 | POLYALKYLENE OXIDE POLYQUATERNARY AMMONIUM BIOCIDES - Disclosed are polyquaternary ammonium polymers containing polyalkylene oxide groups according to formula (I) wherein [A] | 2010-06-24 |
20100158854 | METHOD FOR TREATMENT OF AIRWAY AND APPARATUS AND KIT FOR USE THEREWITH - A method of treating an airway in a mammalian body having a mouth, soft palate, uvula, throat and tongue. An implant-forming material is introduced into at least one of the soft palate and uvula for treating at least one of snoring and sleep apnea. An apparatus and kit are provided. | 2010-06-24 |
20100158855 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - The present invention provides methods to treating inflammation related disease and disorders such as an autoimmune disease and autoimmune related uveitis by administering compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. The composition comprises a formulation of a fumagillol derivative that retains anti-inflammation activity and is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. | 2010-06-24 |
20100158856 | Assays and methods using biomarkers - Methods and assays examining expression of one or more biomarkers in a mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of one or more such biomarkers is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Certain biomarkers which may be examined include fucosyltransferases, in particular fucosyltransferase 3 (FUT3) and/or fucosyltransferase 6 (FUT6), as well as sialyl Lewis A and/or X antigens. Kits and articles of manufacture are also provided. | 2010-06-24 |
20100158857 | Compositions and methods for the inhibition of endothelial nitric oxide synthase activity - The present invention relates to the treatment and prevention of the toxic effects associated with increased nitric oxide synthase activity in endothelial cells. In particular, the present invention relates to compounds and methods of treatment that inhibit the nitric oxide synthases present in endothelial cells and methods for treating diseases using such compounds and methods. | 2010-06-24 |
20100158858 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES - In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting VEGF mRNA translation by orally administering said medicament once, twice or thrice daily to the subject. | 2010-06-24 |
20100158859 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER - The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2010-06-24 |
20100158860 | HETEROCYCLIC ANTIVIRAL COMPOUNDS - Compounds having the formula I wherein A, R | 2010-06-24 |
20100158861 | TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA WITH COMPOSITIONS COMPRISING EXTRACTS OF ASTRAGALUS MEMBRANACEUS - The teachings provided herein generally relate to the preparation and uses of compositions comprising extracts of | 2010-06-24 |
20100158862 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-06-24 |
20100158863 | TRIAZOLOANILINOPYRIMIDINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS - A quinazoline derivative of formula (I), or a pharmaceutically acceptable salt thereof: formula (I) for use in treatment of prevention of a flaviviridae infection. | 2010-06-24 |
20100158864 | ANTIVIRAL PRODUCT - The present invention relates to a novel antiviral product, its use in the treatment of hepatitis C, and its process of manufacture. More particularly it relates to a characterised product exhibiting antiviral activity against Hepatitis C virus (HCV). In one embodiment there is provided a single herb | 2010-06-24 |
20100158865 | Inhibitor of endogenous human interferon-gamma - The invention relates to an inhibitor of endogenous human interferon-gamma (hIFN-ϝ) in autoimmune diseases, especially in multiple sclerosis. More precisely, the invention relates to inactivated protein derivatives of the hIFN-ϝ with preserved affinity to the hIFN-ϝ receptor. The derivatives represent genetically modified variants of hIFN-ϝ, where the C-terminal part of the molecule is either deleted or replaced with a polypeptide sequence of another human protein and a recombinant hIFN-ϝ, inactivated by physical or chemical methods. | 2010-06-24 |
20100158866 | PREDICTION OF HCV TREATMENT RESPONSE - The present invention is based on the discovery that in patients infected with Hepatitis C Virus Genotype 1 (HCV-1) or Genotype 4 (HCV-4), a beneficial response to a treatment that includes interferon alpha, ribavirin and a HCV polymerase inhibitor could be predicted if the patient's HCV RNA level becomes undetectable in as short as two weeks post treatment. | 2010-06-24 |
20100158867 | PARAMYXOVIRUS VECTOR ENCODING ANGIOGENESIS GENE AND USE THEREOF - The present invention provides Paramyxovirus vectors encoding angiogenic genes and use of the same. The use of Paramyxovirus vectors enables effective transfer of angiogenic genes into individual tissues. FGF2 gene transferred into ischemic tissues in vivo induces expression of angiogenic genes without causing edema, and prevents necrosis due to ischemia. The vectors of the present invention are suitable for gene therapy targeted to ischemic tissues. | 2010-06-24 |
20100158868 | Use of Fetal Cells for the Treatment of Genetic Diseases - The present invention provides iPS and stem cells derived from fetal somatic cells derived from a fetus in utero or from cord blood. The iPS and stem cells can be stored or used to treat genetic diseases. | 2010-06-24 |
20100158869 | COMPOSITIONS, DEVICES AND METHODS FOR TREATMENT OF HUNTINGTON'S DISEASE THROUGH INTRACRANIAL DELIVERY OF SIRNA - The present invention provides devices, small interfering RNAs, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, systems, and methods for treating Huntington's disease in vivo without impairment of cell endoplasmic reticulum, spontaneous motor activity, or locomotor activity of a patient. | 2010-06-24 |
20100158870 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - The present invention relates to a novel bacteriophage, more particularly, a bacteriophage that has a specific bactericidal activity against | 2010-06-24 |
20100158871 | Sickled erythrocytes with antitumor molecules induce tumoricidal effects - The present invention provides erythrocytes or nucleated erythrocyte precursors from animals or patients with at least one S hemoglobin allele which are capable of selectively localizing in tumor vasculature resulting in vaso-occlusion, hemolysis and heme release. A tumoricidal effect is achieved when these cells are administered in before during or after administration of (i) an agent(s) that interferes with degradation of reactive oxygen species, (ii) impairs glucose uptake and/or (iii) chemotherapy. These cells also carry oncolytic viruses, antitumor proteins, multidrug resistant proteins, chemotherapy, monoclonal antibodies, superantigens, superantigen conjugates and fusion proteins, siRNAs, plasmids and non-protein toxins and attenuated tumoricidal bacterial cells specifically into the tumors and induce a tumoricidal effect. | 2010-06-24 |
20100158872 | Cardiomyocyte Cell Populations - The present invention provides methods for inducing the differentiation of cardiac progenitor cells and cell populations produced by the methods of the invention. The invention further provides a method of screening for agents that affect cardiomyocytes, and a method of cardiomyocyte replacement therapy. | 2010-06-24 |
20100158873 | METHOD FOR EXTRACTING AND SELECTING CELLS - Method for selecting cells, comprising at least one at least partially combined step of enzymatic digestion and of selection in culture. | 2010-06-24 |
20100158874 | Compositions and Methods for Treating Peripheral Vascular Diseases - The invention relates to methods for producing endothelial cells, pericytes and/or muscle cells (in particular smooth muscle cells), cell preparations and pharmaceutical compositions comprising the cells or preparations, and the use of the cells, preparations and compositions in research or commercial applications. In aspects, the invention provides a method of treating a patient with a condition involving endothelial cells, endothelial precursor cells, pericytes and/or muscle cells, such as a peripheral vascular disease, comprising administering to the patient endothelial precursor cells, endothelial cells, pericytes and/or muscle cells obtained from multipotent CD45 | 2010-06-24 |
20100158875 | MUSCLE DERIVED CELLS FOR THE TREATMENT OF GASTRO-ESOPHAGEAL PATHOLOGIES AND METHODS OF MAKING AND USING THE SAME - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration of symptoms for gastro-esophageal pathologies like gastro-esophageal reflux. | 2010-06-24 |
20100158876 | PROCESS FOR THE PREPARATION OF STEM CELLS FROM HUMAN MUSCLE TISSUE AND ADIPOSE TISSUE, AND STEM CELLS OBTAINABLE BY THIS PROCESS - The invention relates to a process for the preparation of the human stem cells from muscle tissue or adipose tissue. The process provides for the incubation of cells obtained from a sample of muscle tissue or adipose tissue in a medium comprising BSA, Bfgf, EGF, VEGF, LIF, heparin and usual inorganic salts, natural acids and vitamins necessary for the growth of mamalian cells. The invention relates also to the human muscle stem cells (hMSC) and human adipose tissue cells (hFSC) obtainable by this process. | 2010-06-24 |
20100158877 | TREATMENT OF LUNG AND PULMONARY DISEASES AND DISORDERS - Compositions and methods of using cells derived from umbilical cord tissue to stimulate and support lung tissue angiogenesis, to improve blood flow to lung tissue, to regenerate, repair, and improve lung tissue damaged by lung disease, disorder and/or injury, and to protect lung tissue from damage caused by lung disease, disorder and/or injury in a patient. | 2010-06-24 |
20100158878 | TARGET POPULATIONS OF OLIGODENDROCYTE PRECURSOR CELLS AND METHODS OF MAKING AND USING SAME - This application provides for enriched target populations oligodendrocyte precursor cells (OPCs) that can differentiate into oligodendrocytes. The target OPCs may be expanded and optionally subjected to conditions to induce their differentiation into oligodendrocytes. The target OPCs and their progeny are useful for the treatment of disease associated with demyelination of central nervous system axons. | 2010-06-24 |
20100158879 | EXPRESSION CASSETTE AND VECTOR FOR TRANSIENT OR STABLE EXPRESSION OF EXOGENOUS MOLECULES - The disclosure provides an expression cassette and a vector comprising the cassette for expression of a polynucleotide. The expression cassette includes a promoter/enhancer, an intervening region, and a polyadenylation signal domain. Expression systems and methods of using the expression cassette and vector are also provided. | 2010-06-24 |
20100158880 | REGENERATION AND REPAIR OF NEURAL TISSUE FOLLOWING INJURY - Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury are disclosed. | 2010-06-24 |
20100158881 | ACTIVATED DUAL SPECIFICITY LYMPHOCYTES AND THEIR METHODS OF USE - The present invention relates to preventive, therapeutic, and diagnostic compositions and methods employing lymphocytes having T-cell receptors and chimeric receptors. In particular, the invention relates to pre-selected dual-specificity lymphocytes having endogenous T-cell receptors and chimeric T-cell receptors that recognize a strong antigen and tumor associated antigens where the pre-selected population of adoptively transferred lymphocytes is activated by in vivo immunization, thereby increasing the effectiveness of adoptive immunotherapy. | 2010-06-24 |
20100158882 | IMMUNOMODULATING PROBIOTIC LACTIC ACID BACTERIA - The present invention relates to immuno modulating probiotic lactic acid bacteria, to methods wherein the bacteria are used to reduce allergy, and to food products wherein the bacteria may be in incorporated to reduce allergy upon consumption of the product. Preferred probiotic lactic acid bacteria stimulate the Th1 and/or Th3 responses and/or represses Th2 responses as may be determined by the cytokine profiles that are induced in human peripheral blood mononuclear cells upon coincubation with the lactic acid bacteria. | 2010-06-24 |
20100158883 | Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis - A method of suppressing angiogenesis in a mammal (e.g., for treating tumors, tumor metastasis or a condition that would benefit from decreased angiogenesis) comprises the step of administering to the mammal an angiostatically effective amount of a pharmaceutical composition comprising an isolated antiangiogenic truncated tryptophanyl-tRNA synthetase (TrpRS) polypeptide or an isolated nucleic acid that comprises a polynucleotide sequence that encodes the truncated TrpRS polypeptide. The truncated TrpRS polypeptide comprises residues 71-471 of SEQ ID NO: 10, residues 48-471 of SEQ ID NO: 10, or a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO: 10 with polymorphonuclear leucocyte elastase. | 2010-06-24 |
20100158884 | Cascade - The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient. | 2010-06-24 |
20100158885 | METHOD AND MATERIAL FOR SITE ACTIVATED COMPLEXING OF BIOLOGIC MOLECULES - Methods of and compositions for producing and using plant-based materials are provided. The methods include using biopolymers or their synthetic equivalents combined with a stable source of reactive oxygen species that when applied to or combined with a separate source of oxido-reducing enzyme or catalyst will cause the formation of an activated biopolymer with increased protein binding affinity and microbial control activities. | 2010-06-24 |
20100158886 | Triple acting antimicrobials that are refractory to resistance development - Multi-drug resistant superbugs are a persistent problem in modern health care. This invention provides an antimicrobial endolysin-Lysostaphin triple fusion protein, comprising (1) an endolysin CHAP endopeptidase domain, (2) an endolysin amidase domain, and (3) a Lysostaphin glycyl-glycine endopeptidase domain. The domains are derived from two proteins that show antimicrobial synergy when used in combination. The protein has specificity and exolytic activity for the peptidoglycan cell wall of untreated, live | 2010-06-24 |
20100158887 | DIRECT APPLICATION OF NON-TOXIC CROSSLINKING REAGENTS TO RESIST PROGRESSIVE SPINAL DEGENERATION AND DEFORMITY - A method of treatment of native, non-denatured tissue to increase resistance to tearing, fissuring, rupturing, and/or delamination, comprising the step of: contacting at least a portion of the tissue with an effective amount of a reagent that increases crosslinks in the tissue. | 2010-06-24 |
20100158888 | USE OF ALKALINE PHOSPHATASE TO MAINTAIN HEALTHY TISSUE MASS IN MAMMALS - Embodiments of the present invention relate to the use of placental alkaline phosphatase, and other members of the alkaline phosphatase family, to enhance protein synthesis in the muscle as well as the survival of non-cancerous differentiated cells in the muscle, adipose and other tissues. The ability of alkaline phosphatase to selectively enhance the survival of healthy cells and increase protein synthesis has many therapeutic applications. The use of alkaline phosphatase may prevent the loss of body weight and muscle mass typically experienced by diseased (such as cancer) or aging patients, or developing fetuses subjected to harmful conditions, or by patients who are treated with a toxic therapy including chemotherapy. | 2010-06-24 |
20100158889 | ENHANCING THE EFFECT OF THERAPEUTIC PROTEINS ON THE CENTRAL NERVOUS SYSTEM - The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid sequence. Specifically the inventors disclose the attachment of a 4-15 acidic amino acid sequence to human β-glucuronidase by construction of a fusion protein. This molecule is useful in the treatment of type VII mucopolysaccharidosis when administered to a patient. | 2010-06-24 |
20100158890 | USE OF THROMBIN MUTANTS TO INHIBIT THE ANTICOAGULATION EFFECT OF THROMBIN INHIBITORS - The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban. The present invention further provides a method for quantifying the concentration of an anticoagulant in the plasma or whole blood of a patient using a variant prothrombin or thrombin titration assay. | 2010-06-24 |
20100158891 | Human Coagulation Factor VII Variants - The present invention encompasses isolated human coagulation Factor VII variants comprising a substitution of Phe in position 374 of SEQ ID NO 1 with another amino acid residue. | 2010-06-24 |
20100158892 | PEST CONTROL - The present invention relates to novel rodent control agents comprising antibodies, or antigen-binding fragments thereof, that bind to proteins expressed in rodents and in particular antibodies or antigen-binding fragments that bind to proteins expressed in the gastrointestinal (GI) tract of rodents, as well as to methods of making such novel rodent control agents. The invention further extends to novel antibodies and antigen-binding fragments for use in rodent control as well as to methods of controlling rodents through the use of such antibodies, antigen binding fragments and novel rodent control agents. | 2010-06-24 |
20100158893 | SYSTEMS AND METHODS FOR OBTAINING IMMUNOGLOBULIN FROM BLOOD - The present disclosure relates generally to systems for obtaining a pharmaceutically acceptable immunoglobulin from blood of a donor comprising a first conduit configured to convey blood from the donor to a substrate, wherein said blood includes at least one first component and at least one second component, said first component of the blood including immunoglobulin, and wherein said substrate is adapted to bind immunoglobulin; and a second conduit configured to convey at least a portion of the second component of the blood from the first conduit to the donor. | 2010-06-24 |